Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03712813 · ClinicalTrials.gov registry record · NA

Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors

A NA study of Breast Cancer, sponsored by Indiana University.

Completed
Registry status
NA
Development phase
72
Enrollment target
1
Study location

NCT03712813: Completed NA study of Breast Cancer, sponsored by Indiana University.

NCT03712813 is a NA study of Breast Cancer that has completed, run by Indiana University. The registered enrollment target is 72 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03712813, a NA study of Breast Cancer, has completed, sponsored by Indiana University.

COMPLETED
Registry status
NA
Development phase
72 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the effect of low intensity vibration (LIV) delivered for 10 minutes twice daily for 12 months on skeletal muscle function, in terms of energetic capacity measured by power generation on a stationary bicycle, among patients with early stage breast cancer planned to initiate aromatase inhibitor therapy who do not currently participate in regular exercise, compared to a wait- listed control.

Primary Outcome

Peak power will be measured using the Power Protocol-B

Conditions Studied

Interventions

  • DEVICE Macrodyne LivMD plate

Study Locations (1)

Indiana

  • Indiana University Melvin & Bren Simon Cancer Center - Indianapolis

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2019-10-02
Est. Completion 2025-12-18
Phase NA
Indiana University

890 total trials

What the finished NCT03712813 record still lists

NCT03712813 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Macrodyne LivMD plate is the first listed.

NCT03712813 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT03712813 about?

NCT03712813 is a clinical study titled "Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors". The purpose of this study is to compare the effect of low intensity vibration (LIV) delivered for 10 minutes twice daily for 12 months on skeletal muscle function, in terms of energetic capacity measured by power generation on a stationary bicycle, among patients with early stage breast cancer plann...

What is the current status of trial NCT03712813?

This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2019-10-02. Estimated completion is 2025-12-18.

What conditions does trial NCT03712813 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03712813?

The interventions under investigation include: Macrodyne LivMD plate (DEVICE).

Who is sponsoring clinical trial NCT03712813?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03712813 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03712813's enrollment target sits among peer trials

72 685th of 1224 higher than 533 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02359253 · 72 participants · NA

    Robot Aided Rehabilitation - Intervention

  • NCT02962661 · 72 participants · Phase 1

    Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

  • NCT03113643 · 72 participants · Phase 1

    SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • NCT03187535 · 72 participants · NA

    Effect of TEAS on PONV After Spinal Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03712813, the US trial registry maintained by the National Library of Medicine. NCT03712813 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.